Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg, 300 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea

NCT06902545 is registered in ClinicalTrials.gov with Astellas Pharma Korea, Inc. as lead sponsor.

NCT NCT06902545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06902545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg, 300 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea
Lead sponsor
Astellas Pharma Korea, Inc.
Phase
Observational
Overall status
Recruiting
Start date
April 3, 2025
Completion date
July 31, 2030
Enrollment
377 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced unresectable gastric adenocarcinoma or cancer, locally advanced unresectable gastroesophageal junction (gej) adenocarcinoma or cancer, metastatic gastric adenocarcinoma or cancer, metastatic gastroesophageal junction (gej) adenocarcinoma